Search

Your search keyword '"R. Facchetti"' showing total 165 results

Search Constraints

Start Over You searched for: Author "R. Facchetti" Remove constraint Author: "R. Facchetti"
165 results on '"R. Facchetti"'

Search Results

51. Uric Acid, Hypertensive Phenotypes, and Organ Damage: Data from the Pamela Study.

52. Elevated resting heart rate as independent in-hospital prognostic marker in COVID-19.

53. White-Coat Hypertension: Pathophysiological and Clinical Aspects: Excellence Award for Hypertension Research 2020.

54. COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study.

56. Targeting persistent normal left ventricular geometry in the general population: a 25-year follow-up study.

57. Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study.

58. Adding Home and/or Ambulatory Blood Pressure to Office Blood Pressure for Cardiovascular Risk Prediction.

59. Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials.

60. Office and Out-of-Office Blood Pressure Changes Over a Quarter of Century: Findings From the PAMELA Study.

61. Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers.

63. THE role of metabolic syndrome in blood pressure control and pulse wave velocity progression over a 3.5 years in treated hypertensive PATIENTS.

64. Clinical correlates and subclinical cardiac organ damage in different extreme dipping patterns.

65. Limited reproducibility of MUCH and WUCH: evidence from the ELSA study.

66. Self-reported prevalence of sleep disorders among medical and nursing students.

67. Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project.

68. Left ventricular hypertrophy in isolated and dual masked hypertension.

69. Left ventricular mass and incident out-of-office hypertension in a general population.

70. The impact of systolic and diastolic blood pressure variability on mortality is age dependent: Data from the Dublin Outcome Study.

71. Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?

72. High-normal blood pressure and abnormal left ventricular geometric patterns: a meta-analysis.

73. Incident Left Ventricular Hypertrophy in Masked Hypertension.

74. Relationship between vascular damage and left ventricular concentric geometry in patients undergoing coronary angiography: a multicenter prospective study.

75. Risk behaviors among Italian healthcare students: a cross-sectional study for health promotion of future healthcare workers.

76. Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis.

77. High Normal Blood Pressure and Left Ventricular Hypertrophy Echocardiographic Findings From the PAMELA Population.

78. Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries: findings from the Blood Pressure control rate and CArdiovascular Risk profilE study.

79. Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction.

80. Relationships between residual blood pressure variability and cognitive function in the general population of the PAMELA study.

81. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting.

82. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.

83. Risk of new-onset metabolic syndrome associated with white-coat and masked hypertension: data from a general population.

84. Big Data and Blood Pressure Control: Insights from the PAMELA and BP-CARE Study Cohorts.

85. Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study.

86. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities.

87. The importance of pulse pressure on cardiovascular risk and total mortality in the general population: Is sex relevant?

88. Night-time heart rate nondipping: clinical and prognostic significance in the general population.

89. Determinants of carotid-femoral pulse wave velocity progression in hypertensive patients over a 3.7 years follow-up.

90. Long-term changes in left ventricular mass echocardiographic findings from a general population.

92. Is night-time hypertension worse than daytime hypertension? A study on cardiac damage in a general population: the PAMELA study.

93. Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population.

94. Prognostic impact of late gadolinium enhancement in the risk stratification of heart transplant patients.

95. Annexin A5 in treated hypertensive patients and its association with target organ damage.

96. Differential incremental value of ultrasound carotid intima-media thickness, carotid plaque, and cardiac calcium to predict angiographic coronary artery disease across Framingham risk score strata in the APRES multicentre study.

97. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.

98. Prognostic relevance of electrocardiographic Tpeak-Tend interval in the general and in the hypertensive population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study.

99. New-onset left atrial enlargement in a general population.

100. Do Combined Electrocardiographic and Echocardiographic Markers of Left Ventricular Hypertrophy Improve Cardiovascular Risk Estimation?

Catalog

Books, media, physical & digital resources